JP2004518631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518631A5 JP2004518631A5 JP2002530039A JP2002530039A JP2004518631A5 JP 2004518631 A5 JP2004518631 A5 JP 2004518631A5 JP 2002530039 A JP2002530039 A JP 2002530039A JP 2002530039 A JP2002530039 A JP 2002530039A JP 2004518631 A5 JP2004518631 A5 JP 2004518631A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- microparticle
- antigen
- group
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 60
- 239000011859 microparticle Substances 0.000 description 47
- 239000000427 antigen Substances 0.000 description 40
- 102000036639 antigens Human genes 0.000 description 38
- 108091007433 antigens Proteins 0.000 description 38
- 238000000034 method Methods 0.000 description 38
- 239000013598 vector Substances 0.000 description 33
- 239000002773 nucleotide Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 239000010419 fine particle Substances 0.000 description 24
- 229920000642 polymer Polymers 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- MJWYCUZCRGLCBD-BGZMIMFDSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O MJWYCUZCRGLCBD-BGZMIMFDSA-N 0.000 description 9
- 108010008118 glutamyl-leucyl-valyl-isoleucyl-serine Proteins 0.000 description 9
- 229920002521 macromolecule Polymers 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 7
- 241000710929 Alphavirus Species 0.000 description 6
- 229940061720 alpha hydroxy acid Drugs 0.000 description 5
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 5
- -1 gp140 Proteins 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 229920002732 Polyanhydride Polymers 0.000 description 4
- 229920001710 Polyorthoester Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000037353 metabolic pathway Effects 0.000 description 4
- 239000002745 poly(ortho ester) Substances 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- 229920002721 polycyanoacrylate Polymers 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- 241000710942 Ross River virus Species 0.000 description 3
- 241000710961 Semliki Forest virus Species 0.000 description 3
- 241000710960 Sindbis virus Species 0.000 description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 3
- 241000710772 Yellow fever virus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003067 hemagglutinative effect Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 229940051021 yellow-fever virus Drugs 0.000 description 3
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical group O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23610500P | 2000-09-28 | 2000-09-28 | |
| US31590501P | 2001-08-30 | 2001-08-30 | |
| PCT/US2001/030540 WO2002026209A2 (en) | 2000-09-28 | 2001-09-28 | Microparticles for delivery of the heterologous nucleic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004518631A JP2004518631A (ja) | 2004-06-24 |
| JP2004518631A5 true JP2004518631A5 (enExample) | 2008-11-13 |
Family
ID=26929462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002530039A Pending JP2004518631A (ja) | 2000-09-28 | 2001-09-28 | 異種核酸の送達のための微粒子 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20030138453A1 (enExample) |
| EP (1) | EP1322287B1 (enExample) |
| JP (1) | JP2004518631A (enExample) |
| CN (1) | CN1468089B (enExample) |
| AT (1) | ATE320792T1 (enExample) |
| AU (1) | AU9489701A (enExample) |
| BR (1) | BR0114305A (enExample) |
| CA (1) | CA2421683C (enExample) |
| DE (1) | DE60118228T2 (enExample) |
| DK (1) | DK1322287T3 (enExample) |
| ES (1) | ES2260291T3 (enExample) |
| MX (1) | MXPA03002640A (enExample) |
| PT (1) | PT1322287E (enExample) |
| SG (1) | SG137691A1 (enExample) |
| WO (1) | WO2002026209A2 (enExample) |
| ZA (1) | ZA200301744B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| EP1141314A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2457100A (en) * | 1999-02-26 | 2000-09-14 | Chiron S.P.A. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| WO2001051500A1 (en) | 2000-01-14 | 2001-07-19 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| AU2003219805B2 (en) * | 2002-02-15 | 2009-06-04 | Eisai Inc. | Electroporation methods for introducing bioactive agents into cells |
| JP4646516B2 (ja) | 2002-02-20 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 吸着したポリペプチド含有分子を有する微粒子 |
| ATE489969T1 (de) * | 2002-06-20 | 2010-12-15 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
| US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| WO2004032860A2 (en) | 2002-10-07 | 2004-04-22 | Chiron Corporation | Hiv vaccine formulations |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| US20050191358A1 (en) * | 2003-01-14 | 2005-09-01 | Derek O' Hagan | Microparticles with adsorbed polynucleotide-containing species |
| EP1608403A2 (en) * | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| WO2004096136A2 (en) * | 2003-04-25 | 2004-11-11 | Chiron Corporation | Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| EP1628680B1 (en) * | 2003-05-15 | 2012-10-24 | Novartis Vaccines and Diagnostics, Inc. | Hiv polynucleotides and polypeptides derived from botswana mj4 |
| ES2596553T3 (es) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
| FR2862306B1 (fr) * | 2003-11-17 | 2008-05-30 | Aventis Pasteur | Composition vaccinale |
| GB0416120D0 (en) * | 2004-07-19 | 2004-08-18 | Health Prot Agency | Stable compositions containing OMV's |
| AU2005334819B2 (en) * | 2004-11-15 | 2011-11-24 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant |
| FR2878746B1 (fr) | 2004-12-02 | 2007-02-23 | Vetoquinol Sa Sa | Nouvelle composition pharmaceutique utilisable dans le domaine des vaccins |
| FR2893254B1 (fr) | 2005-11-14 | 2007-12-21 | Biomerieux Sa | Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral et son utilisation prophylactique, therapeutique et diagnostique. |
| US9393215B2 (en) | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| WO2009134769A1 (en) | 2008-04-28 | 2009-11-05 | Novartis Ag | Nanoparticles for use in pharmaceutical compositions |
| US20120177741A1 (en) * | 2009-09-29 | 2012-07-12 | Eyegate Pharmaceuticals, Inc. | Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| CN102933267B (zh) | 2010-05-28 | 2015-05-27 | 泰特里斯在线公司 | 交互式混合异步计算机游戏基础结构 |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| US20120244222A1 (en) * | 2011-03-25 | 2012-09-27 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| MX344635B (es) * | 2012-03-23 | 2017-01-04 | Amicrobe Inc | Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido. |
| EP2869842A1 (en) * | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
| RU2019121801A (ru) | 2016-12-14 | 2021-01-15 | Лигандал, Инк. | Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка |
| CN110740744A (zh) | 2017-04-06 | 2020-01-31 | 艾麦克罗比公司 | 性能和安全性增强的局部施用的抗微生物剂的组合物和应用 |
| AU2018285694B2 (en) | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| WO2022051024A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
| CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
| ES3030145T8 (en) * | 2021-05-06 | 2025-08-07 | Hipra Scient S L U | Sars-cov-2 subunit vaccine |
| CN114917334B (zh) * | 2022-07-21 | 2022-10-28 | 天津三江永利生物科技有限公司 | 一种水包油包水型复合疫苗佐剂以及制备方法和应用 |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE634667A (enExample) * | 1962-07-11 | |||
| FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| DE69418699T2 (de) * | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| US5603960A (en) * | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| GB9412273D0 (en) * | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
| US5842723A (en) * | 1996-11-25 | 1998-12-01 | Burex Automotive America, Inc. | Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle |
| US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
| ES2195317T3 (es) * | 1997-01-30 | 2003-12-01 | Chiron Corp | Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias. |
| US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| PT1042001E (pt) * | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| AU2221600A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| WO2000050006A2 (en) * | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
| WO2001081609A2 (en) * | 2000-03-22 | 2001-11-01 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| WO2002026212A2 (en) * | 2000-09-28 | 2002-04-04 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
-
2001
- 2001-09-28 US US09/967,464 patent/US20030138453A1/en not_active Abandoned
- 2001-09-28 SG SG200502574-7A patent/SG137691A1/en unknown
- 2001-09-28 JP JP2002530039A patent/JP2004518631A/ja active Pending
- 2001-09-28 MX MXPA03002640A patent/MXPA03002640A/es active IP Right Grant
- 2001-09-28 WO PCT/US2001/030540 patent/WO2002026209A2/en not_active Ceased
- 2001-09-28 DE DE60118228T patent/DE60118228T2/de not_active Expired - Lifetime
- 2001-09-28 AT AT01975584T patent/ATE320792T1/de active
- 2001-09-28 EP EP01975584A patent/EP1322287B1/en not_active Expired - Lifetime
- 2001-09-28 PT PT01975584T patent/PT1322287E/pt unknown
- 2001-09-28 ES ES01975584T patent/ES2260291T3/es not_active Expired - Lifetime
- 2001-09-28 BR BR0114305-0A patent/BR0114305A/pt not_active IP Right Cessation
- 2001-09-28 CN CN018164595A patent/CN1468089B/zh not_active Expired - Fee Related
- 2001-09-28 AU AU9489701A patent/AU9489701A/xx not_active Withdrawn
- 2001-09-28 DK DK01975584T patent/DK1322287T3/da active
- 2001-09-28 CA CA002421683A patent/CA2421683C/en not_active Expired - Fee Related
-
2003
- 2003-03-03 ZA ZA2003/01744A patent/ZA200301744B/en unknown
-
2007
- 2007-01-16 US US11/653,792 patent/US20080026071A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1322287B1 (en) | Microparticles for delivery of the heterologous nucleic acids | |
| Matić et al. | Current view on novel vaccine technologies to combat human infectious diseases | |
| Vajdy et al. | Mucosal adjuvants and delivery systems for protein‐, DNA‐and RNA‐based vaccines | |
| Bloom et al. | Self-amplifying RNA vaccines for infectious diseases | |
| JP4601168B2 (ja) | 吸着表面を有する微小粒子、それを作製する方法、およびその使用 | |
| JP3835826B2 (ja) | 非経口アジュバントとしての細菌性ａｄｐ−リボシル化毒素の無毒化された変異体 | |
| JP2002537102A5 (enExample) | ||
| Strugnell et al. | Vaccine antigens | |
| EP1585542B1 (en) | Immunogenic compositions containing phospholipid | |
| Plotkin | Six revolutions in vaccinology | |
| Aljabali et al. | Current state of, prospects for, and obstacles to mRNA vaccine development | |
| WO2003059381A2 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
| McKenzie et al. | Nucleic acid vaccines: tasks and tactics | |
| JP6013400B2 (ja) | 免疫応答を誘導するための組成物 | |
| CN117298264A (zh) | 基于流感病毒ha蛋白和新冠病毒s蛋白的组合物和疫苗 | |
| JP2002528123A (ja) | 遺伝子免疫のための核酸構築物 | |
| Yu et al. | A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice | |
| WO2023130637A1 (en) | Vaccines and compositions based on sars-cov-2 s protein | |
| Ramsay et al. | DNA immunization | |
| Webster | Potential advantages of DNA immunization for influenza epidemic and pandemic planning | |
| WO2003066833A2 (en) | Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies | |
| EP1596834B1 (en) | Microparticles comprising polynucleotides adsorbed on the surface of or entrapped within the microparticles | |
| Dehari et al. | RNA-Based Vaccines for Infectious Disease | |
| RU2003112234A (ru) | Микрочастицы для доставки гетерологичных нуклеиновых кислот | |
| RU2295954C2 (ru) | Микрочастицы для доставки гетерологичных нуклеиновых кислот |